Skip to content
Screener

Jazz Pharmaceuticals JAZZ Net Change in Cash

Net Change in Cash at other companies

Amgen logo
AmgenAMGN
$1.95B+349%
Alkermes logo
AlkermesALKS
-$768.23M-807%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$426.34M-2,377%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$74.44M-49.3%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$179M+459%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$64.79M-524%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payment of employee withholding taxes related to share-based awards(103.6)(67.2)
Repayments of long-term debt(7.8)(757.8)
Proceeds from employee equity incentive and purchase plans32.911.5
Net cash used in financing activities(78.5)(813.5)
Effect of exchange rates on cash and cash equivalents(0.4)1.7
Net increase (decrease) in cash and cash equivalents452.4(551.0)
Cash and cash equivalents, at beginning of period1,391.92,412.9
Cash and cash equivalents, at end of period$1,844.3$1,861.9

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's net change in cash?
Jazz Pharmaceuticals (JAZZ) reported net change in cash of $452.4M in Q1 2026.
How has Jazz Pharmaceuticals's net change in cash changed year-over-year?
Jazz Pharmaceuticals's net change in cash increased by 182.1% year-over-year, from -$551M to $452.4M.
What is the long-term trend for Jazz Pharmaceuticals's net change in cash?
Over 3 years (2021 to 2024), Jazz Pharmaceuticals's net change in cash has grown at a 24.8% compound annual growth rate (CAGR), from -$466.32M to $906.55M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Jazz Pharmaceuticals's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude